NeuMedics Inc.
NeuMedics Inc.
  • Home
  • Leadership
    • Executive Staff
    • About NeuMedics
  • NM320
    • NM320
  • Contact Us
    • Contact Information
  • More
    • Home
    • Leadership
      • Executive Staff
      • About NeuMedics
    • NM320
      • NM320
    • Contact Us
      • Contact Information
  • Sign In
  • Create Account
  • My Account

  • Signed in as:

  • filler@godaddy.com

  • My Account

  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Leadership
    • Executive Staff
    • About NeuMedics
  • NM320
    • NM320
  • Contact Us
    • Contact Information

Account

  • My Account

  • Sign out

  • Sign In
  • My Account

NM320: A Breakthrough Eye Drop for Retinal Disease

NM320: A Breakthrough Eye Drop for Retinal DiseaseNM320: A Breakthrough Eye Drop for Retinal DiseaseNM320: A Breakthrough Eye Drop for Retinal Disease

A first-of-its-kind therapy that delivers a neuroprotective, anti-inflammatory drug to the back of the eye without injections

NM320: A Breakthrough Eye Drop for Retinal Disease

NM320: A Breakthrough Eye Drop for Retinal DiseaseNM320: A Breakthrough Eye Drop for Retinal DiseaseNM320: A Breakthrough Eye Drop for Retinal Disease

A first-of-its-kind therapy that delivers a neuroprotective, anti-inflammatory drug to the back of the eye without injections

Disease Begins Before Symptoms

The retina is one of the most energy-demanding tissues in the body. As we age, changes in blood flow and cellular metabolism can disrupt energy balance within retinal cells.


When energy demand exceeds supply, mitochondrial dysfunction and oxidative stress develop, damaging retinal cells over time. This process is believed to play a central role in retinal diseases, including dry age-related macular degeneration (AMD).


These changes often begin long before symptoms appear, allowing disease progression to occur silently until vision loss becomes noticeable.


NM320 aims to intervene earlier,  before irreversible degeneration occurs.

Treatment Often Comes Too Late

Most retinal therapies are delivered by intravitreal injections after disease progression, limiting their ability to protect retinal cells early.


These approaches:


  • Treat symptoms rather than underlying drivers 
  • Can be invasive and burdensome 
  • Are difficult to use early in disease 


NM320 offers a new approach: non-invasive retinal protection delivered through an eye drop.

A New Way to Deliver Therapy to the Retina

Delivering therapeutic drug levels to the retina without injections has historically been difficult.

NM320 changes that

By combining a highly lipophilic compound with a proprietary lipid microemulsion, NM320 is designed to reach the back of the eye and deliver therapeutic drug levels directly to retinal tissue.

This approach helps stabilize retinal bioenergetics, reduce oxidative stress, and protect retinal cells.

Learn More

Three Key Advantages of NM320

Targets the root cause

Targets the root cause

Targets the root cause

Reduces oxadative stress and helps protect retinal cells from degeneration

Reaches the retina

Targets the root cause

Targets the root cause

Delivers therapeutic levels of drug to the back of the eye

No injections required

Targets the root cause

No injections required

A non-invasive eye-drop with potential for earlier and broader use

Broad Potential Across Retinal Disease

Our approach has potential across multiple conditions driven by oxidative stress and inflammation, including:


  • Age-related macular degeneration (AMD) 
  • Diabetic retinopathy 
  • Other retinal diseases associated with cellular damage 

Scientific Expertise Behind NM320

NM320 is led by deep expertise in tetracycline chemistry, retinal biology, and drug development, including Mark Nelson, PhD, a leading expert in tetracycline-based therapeutics and mitochondrial biology.

In a recent PharmaFeatures interview, Dr. Nelson discusses how this approach is shaping new retinal therapies.

Read the Full Interview

A New Standard in Retinal Care

NeuMedics is advancing its lead program toward clinical development, with a focus on demonstrating safety, retinal delivery, and early efficacy in patients.

Partner with us to advance a new approach to vision care.

Advancing a new path for retinal protection

   For partnering opportunities, investor inquiries, or additional information:
 

William D. Schwieterman, M.D., CEO

241 West 111th St. #23 | New York, New York 10026

251-377-4828 | w.schwieterman@neumedics.com

Copyright © 2026 NeuMedics Inc.  - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept